Faeth Therapeutics, Inc.

FTH Healthcare Biotechnology

In the quarter to June 2026, EPS grew 27.4% and free cash flow fell 174.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

18.79 1.81 −8.79%
Market cap
$532.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
Current Ratio
5.06 7.70 11.92 11.98 30.38 4.16 0.02 0.48 —
Net Debt/EBITDA
0.96 1.32 1.82 2.16 3.97 0.90 (1.44) (0.32) —
Debt/Equity
0.00 0.00 0.01 0.02 0.01 (0.01) (0.23) (0.80) —
ROE
(74.01%) (58.40%) (40.52%) (38.88%) (81.70%) 32.30% 33.64% 27.58% —
ROA
(61.78%) (50.37%) (35.38%) (35.78%) (42.13%) (178.44%) (1,339.68%) (1,820.86%) —
ROIC
0.00% 0.00% 0.00% 0.00% (4,138.91%) 0.00% 0.00% 0.00% —
Return on Tangible Assets
(121.61%) (81.73%) (54.33%) (47.84%) (24.81%) (122.36%) 98.09% 1,336.75% —
Free Cash Flow per Share
(16.03) (19.76) (22.92) (25.62) (23.07) (234.63) (468.70) (0.35) —
Book value per Share
14.74 30.56 46.43 67.36 105.74 (700.29) (3,731.63) (0.20) —
Free Cash Flow
(20.22) (24.82) (32.04) (39.33) (31.97) (18.91) (8.62) (10.31) —
Other line items

Show all line items

Columns are period end dates